Targeting the Nrf2/HO-1 signaling pathway presents a promising therapeutic strategy for managing neurodegenerative diseases, like multiple sclerosis and potentially other neurodegenerative diseases characterized by similar inflammatory processes. This evidence concerns the gene HMOX1 and multiple sclerosis.